Pharmaceuticals News and Research

RSS
SAGE Therapeutics obtains $20M Series B financing from two investors

SAGE Therapeutics obtains $20M Series B financing from two investors

16 Oct 2013
First Edition: October 16, 2013

First Edition: October 16, 2013

16 Oct 2013
Trovagene launches pharmaceutical alliance to monitor lung cancer patients' EGFR mutational status

Trovagene launches pharmaceutical alliance to monitor lung cancer patients' EGFR mutational status

16 Oct 2013
ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

16 Oct 2013
Research shows inhibition of Rcan1 protein may reduce atherosclerosis in mice

Research shows inhibition of Rcan1 protein may reduce atherosclerosis in mice

16 Oct 2013
Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

16 Oct 2013
Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

16 Oct 2013
Ghrelin hormone released during chronic stress may predispose people to PTSD

Ghrelin hormone released during chronic stress may predispose people to PTSD

16 Oct 2013
House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

15 Oct 2013
Innate Immunotherapeutics moves operations over to Sydney, Australia

Innate Immunotherapeutics moves operations over to Sydney, Australia

15 Oct 2013
Marketing and technical support cooperation for aqueous acrylic enteric system, Acryl-EZE®, launched by Colorcon and Evonik Industries

Marketing and technical support cooperation for aqueous acrylic enteric system, Acryl-EZE®, launched by Colorcon and Evonik Industries

15 Oct 2013
Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

15 Oct 2013
immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies closes €34 million Series D financing round

15 Oct 2013
Colorcon, Evonik partner to market and support Acryl-EZE aqueous acrylic enteric system

Colorcon, Evonik partner to market and support Acryl-EZE aqueous acrylic enteric system

15 Oct 2013
Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

From Xstrahl 15 Oct 2013
State highlights: Md. submits plan to tie overhaul hospital charges to state's economy

State highlights: Md. submits plan to tie overhaul hospital charges to state's economy

15 Oct 2013
Teva gets FDA approval for generic version of TOBI in US

Teva gets FDA approval for generic version of TOBI in US

15 Oct 2013
First Edition: October 14, 2013

First Edition: October 14, 2013

14 Oct 2013
PARP inhibitor drugs and chemotherapy can help women with ovarian cancer live longer

PARP inhibitor drugs and chemotherapy can help women with ovarian cancer live longer

13 Oct 2013
UCLA, Takeda to study how disruption of circadian rhythms promotes type 2 diabetes

UCLA, Takeda to study how disruption of circadian rhythms promotes type 2 diabetes

13 Oct 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback